Purespring to present three posters at the American Society of Nephrology Kidney Week 2025
New information to be presented on the study design and methodology of Purespring’s Phase I/II…
Purespring Therapeutics to Present at Chardan’s 9th Annual Genetic Medicines Conference
Members of the Purespring management team will present at Chardan’s 9th Annual Genetic Medicines Conference.…
Purespring Therapeutics to Participate in the 2025 BofA Healthcare Trailblazers Private Company Conference
Members of the Purespring management team will participate in the 2025 Bank of America Healthcare…
Purespring Therapeutics receives UK CTA approval for Phase I/II clinical trial of PS-002 in patients with primary IgA nephropathy (IgAN)
First patient in Phase I/II clinical trial expected to be enrolled in Q4 2025 UK…
Purespring Therapeutics announce FDA IND clearance for Phase I/II clinical trial for primary IgA nephropathy (IgAN)
PS-002, Purespring’s lead precision nephrology programme, targets the complement pathway known to be a driver…
Purespring Therapeutics granted European Medicines Agency (EMA) orphan drug designation for PS-002 for the treatment of patients with primary IgA nephropathy (IgAN)
EMA designation provides orphan status to medicines being developed for rare conditions that are intended…
Purespring Therapeutics appoints Haseeb Ahmad as Chief Executive Officer
Haseeb Ahmad brings over 25 years of leadership experience in life sciences, most recently serving…
Purespring Therapeutics presents new preclinical data on novel gene therapy for IgA Nephropathy at ASN Kidney Week 2024
Results from the study underpin the potential of Purespring’s lead AAV gene therapy programme, PS-002,…
Purespring Therapeutics raises £80/$105 million in a Series B financing to transform the treatment of kidney diseases
Oversubscribed financing led by Sofinnova Partners in collaboration with Gilde Healthcare, Forbion, British Patient Capital…
Q&A with Alice Brown
July 2024 Can you tell us a bit about yourself and your background and what…